Daily Stock Analysis, CRMD, CorMedix Inc, priceseries

CorMedix Inc. Daily Stock Analysis
Stock Information
Open
8.44
Close
8.29
High
8.57
Low
8.23
Previous Close
8.45
Daily Price Gain
-0.16
YTD High
13.70
YTD High Date
Feb 13, 2019
YTD Low
6.25
YTD Low Date
Jan 2, 2019
YTD Price Change
1.34
YTD Gain
19.28%
52 Week High
13.70
52 Week High Date
Feb 13, 2019
52 Week Low
0.86
52 Week Low Date
May 22, 2018
52 Week Price Change
7.19
52 Week Gain
656.39%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 1. 2017
8.85
Feb 22. 2017
10.94
14 Trading Days
23.57%
Link
LONG
Jun 2. 2017
2.20
Jun 6. 2017
2.31
2 Trading Days
5.09%
Link
LONG
Aug 23. 2017
2.02
Sep 5. 2017
2.22
8 Trading Days
9.84%
Link
LONG
Sep 21. 2017
2.11
Oct 13. 2017
3.20
16 Trading Days
51.54%
Link
LONG
May 30. 2018
1.15
Jun 12. 2018
1.40
9 Trading Days
22.67%
Link
LONG
Jul 26. 2018
2.15
Aug 8. 2018
2.76
9 Trading Days
28.35%
Link
LONG
Sep 20. 2018
3.08
Oct 18. 2018
8.60
20 Trading Days
179.47%
Link
LONG
Dec 4. 2018
6.75
Dec 11. 2018
7.15
4 Trading Days
5.93%
Link
LONG
Jan 2. 2019
6.95
Jan 18. 2019
8.25
12 Trading Days
18.78%
Link
LONG
Feb 8. 2019
9.85
Feb 14. 2019
10.70
4 Trading Days
8.63%
Link
LONG
Mar 27. 2019
9.27
Mar 28. 2019
9.88
1 Trading Days
6.63%
Link
Company Information
Stock Symbol
CRMD
Exchange
NYSE MKT
Company URL
http://www.cormedix.com
Company Phone
908-517-9500
CEO
Mohammed Khoso Baluch
Headquarters
New Jersey
Business Address
1430 HIGHWAY 206, SUITE 200, BEDMINSTER, NJ 07921
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001410098
About

CorMedix, Inc. operates as pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Bridgewater, NJ.

Description

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Bridgewater, New Jersey.